Copy Link Print Information

Daratumumab

(Synonyms: Anti-Human CD38, Human Antibody; HuMax-CD38; JNJ-54767414)
11 Cited Publications
Customer Review

Based on 11 publication(s) in Google Scholar

Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.

For research use only. We do not sell to patients.

  • Purity: 99.10%
  • CAS No.: 945721-28-8
  • Molecular Weight:145.26 kDa
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Daratumumab
  • Experimental Validation Results for Daratumumab
  • Experimental Validation Results for Daratumumab
  • Experimental Validation Results for Daratumumab
  • Experimental Validation Results for Daratumumab
  • Experimental Validation Results for Daratumumab
  • Experimental Validation Results for Daratumumab
  • Experimental Validation Results for Daratumumab
  • Experimental Validation Results for Daratumumab
  • Daratumumab Chemical Structure
    Daratumumab Chemical Structure
CAS No.: 945721-28-8
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Daratumumab:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Daratumumab

More
Customer Validation & Images
In Vivo Efficacy StudyCell Proliferation/Viability AssayBio/Physico-chemical AssayWB
  • In Vivo Efficacy Study
  • Cell Proliferation/Viability Assay
  • In Vivo Efficacy Study
  • WB
  • Cell Proliferation/Viability Assay
  • Bio/Physico-chemical Assay
Keywords
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG1 kappa

  • 1/16

    Flow cytometry analysis of Raji cells labelling CD38 with Daratumumab at 100nM (Red). Goat anti human IgG Fc(Alexa Fluor488) was used as the secondary antibody at 1/400 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).

  • 1/16

    Daratumumab has a significant CDC effect on Raji cells in a dose-dependent manner. The EC50 for this effect is 96.2 and 98.6 ng/mL.

  • 1/16

    Daratumumab purchased from MedChemExpress. Usage Cited in: Nat Biotechnol. 2025 Oct 17. [Abstract]

    Customer Validation
     A single mesodermal tumor was injected into mesodermal CAR-T cells, and the following treatments were administered: untreated group, daratumumab (0.5 or 10 μg/ml) treatment group, or IgG isotype control antibody (10 μg/ml IgG) treatment group. The change in T cell area over time was quantitatively analyzed.

  • 1/16

    Daratumumab purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2025 Oct 7;82(1):352. [Abstract]

    Customer Validation
     ADCC in H929 cells caused by various concentration of Dara (Daratumumab, 1h treatment and 4h NK cell co-culture).

  • 1/16

    Daratumumab purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2025 Oct 7;82(1):352. [Abstract]

    Customer Validation
     Compared with vehicle control, Dara (Daratumumab, i.p. 8 mg/kg per mouse weekly for 3w) cause significantly reduction of xenograft tumors weight and tumor growth.

  • 1/16

    Daratumumab purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2025 Oct 7;82(1):352. [Abstract]

    Customer Validation
     Inhibitor of ALDH1A 673 A remarkably reduce the protein level of CD38, ALDH1A1 and RAR, and RA complement significantly restore the protein level of CD38 and RAR. Dara (Daratumumab, i.p. 8 mg/kg per mouse weekly for 3w).

  • 1/16

    Daratumumab purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2023 Aug 15;29(16):2988-3003. [Abstract]

    Customer Validation
     ADCC capability of INBRX-109 was evaluated in the Promega Jurkat CD16a (V158) ADCC reporter assay using DR5-transfected ExpiCHO-S cells as targets and untransfected cells as negative controls. Daratumumab (5.5 h), the target of which is expressed on Jurkat cells, serves as a positive control.

  • 1/16

    Daratumumab purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2023 Aug 15;29(16):2988-3003. [Abstract]

    Customer Validation
     The ability of INBRX-109 to bind the complement component C1q contained within normal human serum was measured by ELISA. Daratumumab (5.5 h) is used as a positive control.

  • Daratumumab Chemical Structure
    1/16
  • Daratumumab
  • Flow cytometry analysis of Raji cells labelling CD38 with Daratumumab at 100nM (Red). Goat anti human IgG Fc(Alexa Fluor488) was used as the secondary antibody at 1/400 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).
  • Daratumumab has a significant CDC effect on Raji cells in a dose-dependent manner. The EC50 for this effect is 96.2 and 98.6 ng/mL.